Skip to main content
. 2018 Oct 1;2018(10):CD002252. doi: 10.1002/14651858.CD002252.pub4

Comparison 6. Any antihypertensive versus calcium channel blocker (subgrouped by class of drug).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Severe hypertension 5 223 Risk Ratio (M‐H, Fixed, 95% CI) 1.86 [1.09, 3.15]
1.1 Glyceryl trinitrate versus calcium channel blockers 1 36 Risk Ratio (M‐H, Fixed, 95% CI) 1.56 [0.07, 35.67]
1.2 Beta blockers versus calcium channel blockers 1 100 Risk Ratio (M‐H, Fixed, 95% CI) 2.14 [0.96, 4.80]
1.3 Furosemide versus calcium channel blockers 1 41 Risk Ratio (M‐H, Fixed, 95% CI) 1.09 [0.48, 2.44]
1.4 Methyldopa versus calcium channel blockers 2 46 Risk Ratio (M‐H, Fixed, 95% CI) 4.33 [0.82, 22.86]
2 Proteinuria/pre‐eclampsia 5 375 Risk Ratio (M‐H, Random, 95% CI) 1.24 [0.70, 2.19]
2.1 Glyceryl trinitrate versus calcium channel blockers 1 36 Risk Ratio (M‐H, Random, 95% CI) 1.0 [0.10, 9.96]
2.2 Beta blockers versus calcium channel blockers 2 204 Risk Ratio (M‐H, Random, 95% CI) 1.12 [0.24, 5.23]
2.3 Furosemide versus calcium channel blockers 1 41 Risk Ratio (M‐H, Random, 95% CI) 1.67 [0.57, 4.83]
2.4 Merthyldopa versus calcium channel blockers 1 94 Risk Ratio (M‐H, Random, 95% CI) 1.52 [0.79, 2.93]
3 Total reported fetal or neonatal death (including miscarriage) 9 700 Risk Ratio (M‐H, Random, 95% CI) 0.90 [0.52, 1.57]
3.1 Glyceryl trinitrate versus calcium channel blockers 1 36 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Beta blockers versus calcium channel blockers 3 372 Risk Ratio (M‐H, Random, 95% CI) 0.82 [0.46, 1.46]
3.3 Furosemide versus calcium channel blockers 1 41 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 Methyldopa versus calcium channel blockers 4 251 Risk Ratio (M‐H, Random, 95% CI) 3.21 [0.38, 27.40]
4 Small‐for‐gestational age 4 200 Risk Ratio (M‐H, Random, 95% CI) 1.05 [0.64, 1.73]
4.1 Glyceryl trinitrate versus calcium channel blockers 1 36 Risk Ratio (M‐H, Random, 95% CI) 1.0 [0.10, 9.96]
4.2 Beta blockers versus calcium channel blockers 1 103 Risk Ratio (M‐H, Random, 95% CI) 0.96 [0.55, 1.68]
4.3 Furosemide versus calcium channel blockers 1 41 Risk Ratio (M‐H, Random, 95% CI) 0.48 [0.05, 4.85]
4.4 Methyldopa versus calcium channel blockers 1 20 Risk Ratio (M‐H, Random, 95% CI) 2.5 [0.63, 10.00]
5 Preterm birth (< 37 weeks) 6 330 Risk Ratio (M‐H, Random, 95% CI) 0.85 [0.59, 1.23]
5.1 Glyceryl trinitrate versus calcium channel blockers 1 36 Risk Ratio (M‐H, Random, 95% CI) 0.63 [0.20, 1.91]
5.2 Beta blockers versus calcium channel blockers 1 112 Risk Ratio (M‐H, Random, 95% CI) 0.62 [0.34, 1.15]
5.3 Furosemide versus calcium channel blockers 1 41 Risk Ratio (M‐H, Random, 95% CI) 0.95 [0.22, 4.18]
5.4 Methyldopa versus calcium channel blockers 3 141 Risk Ratio (M‐H, Random, 95% CI) 1.18 [0.61, 2.30]
6 Maternal death 1 112 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Beta blockers versus calcium channel blockers 1 112 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Eclampsia 2 204 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Beta blockers versus calcium channel blockers 1 112 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Methyldopa versus calcium channel blockers 1 92 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
8 HELLP syndrome 2 212 Risk Ratio (M‐H, Random, 95% CI) 1.78 [0.38, 8.20]
8.1 Beta blockers versus calcium channel blockers 2 212 Risk Ratio (M‐H, Random, 95% CI) 1.78 [0.38, 8.20]
9 Pulmonary oedema 1 112 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Beta blockers versus calcium channel blockers 1 112 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Need for additional antihypertensive drug/s 5 440 Risk Ratio (M‐H, Random, 95% CI) 1.36 [0.78, 2.36]
10.1 Beta blockers versus calcium channel blockers 2 212 Risk Ratio (M‐H, Random, 95% CI) 1.27 [0.51, 3.20]
10.2 Methyldopa versus calcium channel blockers 3 228 Risk Ratio (M‐H, Random, 95% CI) 1.61 [0.78, 3.34]
11 Elective delivery (induction of labour + elective caesarean section) 3 302 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.82, 1.17]
11.1 Beta blockers versus calcium channel blockers 1 100 Risk Ratio (M‐H, Random, 95% CI) 0.89 [0.69, 1.15]
11.2 Methyldopa versus calcium channel blockers 2 202 Risk Ratio (M‐H, Random, 95% CI) 0.97 [0.61, 1.54]
12 Caesarean section 6 531 Risk Ratio (M‐H, Random, 95% CI) 1.05 [0.86, 1.29]
12.1 Beta blockers versus calcium channel blockers 3 372 Risk Ratio (M‐H, Random, 95% CI) 1.04 [0.77, 1.39]
12.2 Furosemide versus calcium channel blockers 1 41 Risk Ratio (M‐H, Random, 95% CI) 0.95 [0.57, 1.59]
12.3 Methyldopa versus calcium channel blockers 2 118 Risk Ratio (M‐H, Random, 95% CI) 1.51 [0.87, 2.65]
13 Induction of labour 2 252 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.74, 1.34]
13.1 Beta blockers versus calcium channel blockers 1 160 Risk Ratio (M‐H, Random, 95% CI) 1.15 [0.69, 1.92]
13.2 Methyldopa versus calcium channel blockers 1 92 Risk Ratio (M‐H, Random, 95% CI) 0.92 [0.64, 1.33]
14 Placental abruption 3 253 Risk Ratio (M‐H, Random, 95% CI) 1.05 [0.16, 6.86]
14.1 Beta blockers versus calcium channel blockers 2 212 Risk Ratio (M‐H, Random, 95% CI) 0.35 [0.01, 8.30]
14.2 Furosemide versus calcium channel blockers 1 41 Risk Ratio (M‐H, Random, 95% CI) 1.90 [0.19, 19.40]
15 Maternal side‐effects 3 322 Risk Ratio (M‐H, Random, 95% CI) 1.40 [0.85, 2.29]
15.1 Beta blockers versus calcium channel blockers 2 212 Risk Ratio (M‐H, Random, 95% CI) 1.40 [0.85, 2.29]
15.2 Methyldopa versus calcium channel blockers 1 110 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
16 Changed/stopped drug due to side‐effects 3 248 Risk Ratio (M‐H, Random, 95% CI) 1.55 [0.56, 4.31]
16.1 Glyceryl trinitrate versus calcium channel blockers 1 36 Risk Ratio (M‐H, Random, 95% CI) 2.6 [0.13, 50.25]
16.2 Beta blockers versus calcium channel blockers 2 212 Risk Ratio (M‐H, Random, 95% CI) 1.45 [0.49, 4.30]
17 Admission to neonatal or intensive care nursery 4 319 Risk Ratio (M‐H, Random, 95% CI) 0.86 [0.54, 1.37]
17.1 Beta blockers versus calcium channel blockers 2 202 Risk Ratio (M‐H, Random, 95% CI) 0.88 [0.49, 1.58]
17.2 Methyldopa versus calcium channel blockers 2 117 Risk Ratio (M‐H, Random, 95% CI) 0.82 [0.38, 1.78]
18 Respiratory distress syndrome 1 103 Risk Ratio (M‐H, Random, 95% CI) 0.65 [0.27, 1.54]
18.1 Beta blockers versus calcium channel blockers 1 103 Risk Ratio (M‐H, Random, 95% CI) 0.65 [0.27, 1.54]
19 Neonatal hypoglycaemia 1 103 Risk Ratio (M‐H, Random, 95% CI) 0.76 [0.29, 2.05]
19.1 Beta blockers versus calcium channel blockers 1 103 Risk Ratio (M‐H, Random, 95% CI) 0.76 [0.29, 2.05]